Hyperbaric oxygen therapy is one of the most over-marketed treatments in medicine. Some clinics promise neurological recovery. Others sell anti-aging packages for $20,000.
Almost none of those off-label claims are FDA-approved. The chamber hardware comes from a small set of regulated builders. Sechrist Industries, Perry Baromedical, OxyHealth, Summit to Sea, Newtowne Hyperbarics, Healing Chambers International, and ETC Biomedical make most of what is on the market.
The hardware is mostly fine. The marketing wrapped around it is where most of the myths live.
This article walks through 12 of the most common myths. Each one is checked against published evidence, the UHMS list of approved indications, and the FDA's chamber clearance database.
The goal is not to talk you out of HBOT. The goal is to help you spend money where the evidence is solid — and skip the rest.
Myth 1: "HBOT is FDA-approved for most chronic conditions"
This is the biggest misconception in the field. The FDA has cleared hyperbaric chambers as medical devices for 14 specific indications.
Those 14 sit on real evidence. They include decompression sickness, carbon monoxide poisoning, gas gangrene, crush injury, chronic diabetic wounds, osteomyelitis, radiation tissue damage, and a handful of others. The full list is maintained by the Undersea and Hyperbaric Medical Society.
Everything else — autism, ADHD, Lyme, anti-aging, long COVID, Alzheimer's, multiple sclerosis — is off-label. That means a clinic can legally provide HBOT for those uses, but the FDA has not approved them. Insurance generally won't pay for them either. See the HBOT-for-ADHD evidence in detail for the trial-by-trial ADHD evidence breakdown.
If a clinic tells you HBOT is "approved" for your off-label condition, that's a red flag. Ask which indication code they bill under. The honest answer for off-label is "we don't bill insurance — it's cash-pay."
Myth 2: "Soft chambers and hard chambers are the same product"
They are not. The pressure difference alone is enormous.
Hard-shell medical chambers operate at 2.0 to 3.0 atmospheres absolute (ATA), per UHMS protocol guidance. Soft-shell "mild HBOT" chambers operate at 1.3 ATA, with most consumer units capped at 1.3 by FDA clearance.
That gap matters. Most published RCTs use 2.0 to 2.4 ATA, including the wound-healing trials that anchored Medicare coverage.
Studies at 1.3 ATA show smaller, less consistent effects. A 2008 autism trial published in BMC Pediatrics using 1.3 ATA showed modest behavioral changes, but a 2009 follow-up at the same pressure failed to replicate.
The FDA classifies soft-shell chambers under 510(k) Class II clearance for one indication only: acute mountain sickness. Everything else marketed for soft chambers — recovery, anti-aging, cognition — is off-label.
Myth 3: "More pressure is always better"
This is wrong, and dangerous if you act on it.
Above 2.8 ATA, the risk of central nervous system oxygen toxicity rises sharply. Seizures become a measurable hazard, which is why most treatment tables cap at 2.4 to 2.5 ATA for non-emergency use. The US Navy Treatment Table 6, used for decompression sickness, runs at 2.8 ATA and is monitored continuously.
Higher pressure also doesn't improve outcomes for most conditions. The wound-healing literature, summarized in a 2015 Cochrane review, found that 2.0 to 2.4 ATA produced the best risk-adjusted outcomes for diabetic foot ulcers. Pushing to 3.0 ATA added risk without proportional benefit.
For most non-emergency indications, the sweet spot is 2.0 to 2.4 ATA. Clinics that market "extreme pressure" protocols are doing something the evidence does not support.
Myth 4: "HBOT is established treatment for autism"
It is not. This claim has caused real harm to families spending thousands on protocols without published support.
The largest randomized controlled trial, Rossignol et al. 2009 in BMC Pediatrics, reported modest behavioral changes in some children at 1.3 ATA over 40 sessions. The trial had methodological limitations including parent-reported outcomes and a sham arm that wasn't fully blinded.
Granpeesheh et al. 2010 in Research in Autism Spectrum Disorders ran a more rigorous study and found no difference between HBOT and sham. A 2016 systematic review concluded the evidence does not support HBOT for autism.
Some families report changes they attribute to HBOT. Published trials do not back those reports at the level needed for a clinical recommendation.
Families considering HBOT for autism should talk to a pediatric neurologist first. Read the studies directly before paying for a multi-thousand-dollar protocol.
Myth 5: "Aviv Clinics' anti-aging research is settled science"
It is not.
The widely cited Hachmo et al. 2020 study at Tel Aviv University tested HBOT in 35 adults over 60. It reported telomere lengthening and reduced senescent cell counts after 60 daily sessions.
The result is interesting. It is not a replicated finding.
The study had no control group beyond pre/post measurement. Sample size was 35, follow-up was three months. No larger trial has reproduced the telomere result at the time of writing.
The senescent cell methodology has been questioned in the longevity research community. Aviv Clinics has built marketing around this single study, with treatment packages running $40,000 to $50,000+. See Aviv Clinics evidence vs. marketing for the marketing-vs-evidence breakdown.
Before committing, read the original paper, note the sample size and follow-up window, and ask any clinic citing it what independent replication exists. As of 2026, the honest answer is "none at the same scale."
Myth 6: "Insurance covers HBOT for most conditions"
It covers 14 indications. That's it.
Medicare's National Coverage Determination 20.29 lists the conditions Medicare will reimburse. Private insurance generally mirrors this list. Off-label uses — autism, long COVID, anti-aging, traumatic brain injury for most cases — are not covered.
Out-of-pocket pricing typically runs $200 to $500 per session at private clinics, with package deals at $7,500 to $20,000+ for 40-session protocols. Aviv Clinics charges substantially more. Pricing varies by region and chamber type — hospital monoplace sessions billed to Medicare run roughly $109 to $250 facility-side, per CMS HCPCS code G0277 guidance.
If a clinic claims insurance will cover an off-label use, ask them to verify in writing with your insurer before you start. Most will not.
Myth 7: "Mild HBOT at 1.3 ATA produces the same benefits"
Sometimes. Often not.
The pharmacology is straightforward. At 1.3 ATA breathing room air, arterial oxygen tension rises from about 100 mmHg to roughly 130 mmHg.
At 2.4 ATA breathing 100% oxygen — the standard hospital protocol — arterial oxygen tension reaches 1,500 mmHg or higher. The difference is more than tenfold, per physiology data in Tibbles & Edelsberg 1996, NEJM.
For some applications that lower pressure may still produce measurable effects. Mountain sickness reversal at 1.3 ATA is well-documented. For wound healing, angiogenesis, and infection control, the evidence sits at hospital-grade pressures, not mild HBOT.
If you're considering a soft chamber for serious medical indications, ask the studies that justified the purchase to be at the same pressure. They usually aren't.
Myth 8: "HBOT is risk-free"
It is not risk-free. Most sessions are uneventful, but real complications occur.
The most common adverse event is middle ear barotrauma. A Camporesi 2014 review in Undersea & Hyperbaric Medicine put rates at 2% to 10% of patients. The range depends on protocol and patient mix.
More serious risks include pulmonary barotrauma, oxygen toxicity seizures (roughly 1 to 4 per 10,000 sessions at 2.4 ATA), and chamber fires. Chamber fires are rare but catastrophic when they occur.
The 1997 Milan chamber fire killed 11 people and remains a reference incident for fire safety standards. Soft-shell chamber fires have also been documented, most recently in a 2025 Michigan case widely covered in trade publications.
Reputable clinics screen for contraindications, train staff on fire and pressure protocols, and follow NFPA 99 standards for chamber operation. Cheap home setups often don't.
Myth 9: "Home chambers are as safe as clinic chambers"
The hardware is not the same, and home oxygen handling is where most problems start.
Clinic chambers are inspected annually, run by trained technicians, and operate inside facilities built for the pressure and oxygen loads involved. Home soft chambers ship without that infrastructure.
Oxygen concentrators are sold separately. Hose and seal maintenance is the buyer's responsibility.
A 2014 review in Undersea & Hyperbaric Medicine flagged the main home risks. Oxygen leaks, fires from electronics inside the chamber, and bad pressure protocols topped the list.
Soft chambers carry lower absolute risk than hospital chambers. But the user error margin is much smaller.
If you go the home route, source from established manufacturers, never use synthetic clothing inside, and never bring electronics in. Insurance does not cover home chambers in most cases. Setup costs run $7,000 to $25,000 once the chamber, concentrator, and accessories are included.
Myth 10: "HBOT can replace standard medical care"
It cannot, and clinics that imply otherwise should be avoided.
For FDA-approved indications, HBOT works alongside standard care — not instead of it. The Cochrane diabetic wound review noted that HBOT improved healing rates when added to standard wound care, not when used alone.
For off-label uses, no clinical body recommends HBOT alone. The American Academy of Pediatrics has warned against using HBOT to replace evidence-based care for autism. The American Heart Association does not list HBOT in its stroke recovery guidelines.
If a clinic suggests stopping your prescribed meds, antibiotics, or cancer care in favor of HBOT, walk out. Then report them to your state medical board.
Myth 11: "All HBOT clinics meet the same standards"
They do not. The accreditation gap is real and visible.
The Undersea and Hyperbaric Medical Society accredits clinics that meet equipment, staffing, and protocol standards. Roughly 180 of the 1,588 HBOT clinics tracked in the US have UHMS accreditation as of 2026 — about 11%.
The other 89% may still be excellent. Many are not.
UHMS accreditation has four hard requirements:
- A medical director trained in hyperbaric medicine
- Certified techs with CHT or CHRN credentials
- Written emergency protocols
- Yearly chamber inspections
Non-accredited clinics may meet some of these. Many meet none. The gap covers manufacturers too — chambers from Sechrist Industries, Perry Baromedical, OxyHealth, and ETC Biomedical still need trained staff to run them safely.
When booking, ask these questions:
- Is the clinic UHMS-accredited?
- Is there a medical director on staff?
- Are the technicians CHT-certified?
- What chamber make and FDA 510(k) number?
Honest clinics will answer plainly.
Myth 12: "If a celebrity uses it, it must work"
Celebrity endorsements are not evidence. The list of celebrities and athletes using HBOT is long, including NFL players, NBA players, and various Hollywood figures. Their use does not validate clinical claims.
NFL athletes use HBOT for recovery. Whether it helps any individual athlete more than rest, sleep, and standard physical therapy is not well-established in the published literature.
A few small studies show short-term reductions in muscle soreness markers. Larger trials have not consistently replicated the effect.
The same goes for anti-aging endorsements. Most influencers pushing HBOT have a financial tie to a chamber, a clinic, or a brand. Some are just citing the Tel Aviv study.
Disclosure is often absent. Treat these endorsements as marketing, not evidence.
What good evidence for HBOT looks like
When evaluating an HBOT claim, ask four questions:
- Is it FDA-approved? Check the UHMS-recognized list. If yes, the evidence is strong.
- What pressure did the studies use? If supporting trials used 2.0 to 2.4 ATA and the clinic sells a 1.3 ATA protocol, the evidence does not transfer.
- Has the finding been replicated? Single studies — even high-profile ones — should be treated as preliminary until other labs confirm them.
- What does insurance say? Coverage maps almost perfectly onto the conditions where the evidence is strongest.
These four filters will steer you toward HBOT applications worth your money and away from those that are not.
Related reading
- HBOT regulation guide: FDA, UHMS, and clinic accreditation
- HBOT cost in 2026: insurance, out-of-pocket, home chambers
- Hard chamber vs soft chamber HBOT: real clinical differences
- Hyperbaric oxygen therapy safety checklist
Frequently asked questions
Is HBOT a scam?
HBOT is not a scam for the 14 FDA-approved indications. For decompression sickness, carbon monoxide poisoning, gas gangrene, diabetic wounds, and the other approved uses, it is established medical care. Off-label uses are not scams in themselves, but the marketing around them often overstates the evidence. The key is matching what's promised to what the data actually shows.
Does HBOT really work for traumatic brain injury?
The evidence is mixed. Some studies, including military-funded trials at 1.5 to 2.4 ATA, have reported symptomatic improvements in post-concussion patients. Other rigorous trials, including the BIMA study sponsored by the Department of Defense, found HBOT no better than sham for chronic mild TBI. The condition is not FDA-approved and remains investigational. Discuss with a neurologist before paying for a multi-session protocol.
How much does legitimate HBOT cost?
Per-session pricing at private clinics ranges from $200 to $500 in 2026. Hospital sessions billed through insurance for FDA-approved indications are typically covered with copay. Off-label packages run $7,500 to $20,000 for a standard 40-session protocol. Anti-aging packages at high-end clinics can exceed $40,000. Always confirm pricing in writing before starting.
Can HBOT cause permanent damage?
Permanent damage is rare. The most common adverse event, ear barotrauma, usually resolves. Serious complications — oxygen toxicity seizures, pulmonary barotrauma, fire injury — can cause lasting harm. Risk is meaningfully reduced at UHMS-accredited facilities with trained staff and proper screening. Discuss your medical history with the clinic's medical director before starting.
Should I use a home HBOT chamber?
Home use can be reasonable for general wellness if you understand the limits. Soft-shell home units operate at 1.3 ATA, which is below the pressure used in most clinical studies. They are not equivalent to hospital HBOT. They require careful oxygen handling and pose fire risk if used incorrectly. Buy from established manufacturers, follow NFPA 99 fire safety practices, and do not expect outcomes that the published literature has only shown at higher pressures.
Medical disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. HBOT is investigational for most conditions discussed here. Consult your doctor before starting any hyperbaric treatment, especially if you have pre-existing ear, lung, or cardiovascular conditions. Some uses described are off-label, meaning the FDA has not approved hyperbaric oxygen therapy for those indications.
-- The HBOT Finder Team